Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Hannah Willis, Joshua Horns, Kelsey Baron, Allison Bock, Lindsey Fitzgerald, Narendranath Epperla, Harsh Shah, Boyu Hu, Deborah Stephens, Adam Kittai, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2025-6316

Published: 2025

Journal Articles

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 798.

https://doi.org/10.1182/blood-2025-798

Published: 2025

Journal Articles

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Joanna Rhodes, Adam Kittai, Paul Hampel, Xiaoliang Wang, Qianhong Fu, Danni Zhao, Smriti Karwa, Olive Mbah, Ahmed Sawas, Benjamin Wagner, Rachel Myers, Derrick van Beuge, Gregory Maglinte, Erlene Seymour, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2025-2720

Published: 2025

Journal Articles

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Blood (2025) 146 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2025-1532

Published: 2025

Journal Articles

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Graham Wehmeyer, Ryan Jin, Vesna Najfeld, Megan Metzger, Theodora Anagnostou, Patricia Arboleda Ezcurra, Janice Gabrilove, Marina Kremyanskaya, John Mascarenhas, Christian Salib, Ilan Shapira, Jonah Shulman, Suchitra Sundaram, Douglas Tremblay, Adam Kittai

Blood (2025) 146 (Supplement 1): 5674.

https://doi.org/10.1182/blood-2025-5674

Published: 2025

Journal Articles

Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL

Graham Wehmeyer, Adam Kittai, Bailey Fitzgerald, Thomas Marron, Joshua Brody

Blood (2025) 146 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2025-2376

Published: 2025

Journal Articles

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

John Allan, Andrew Lipsky, Seema Bhat, Suchitra Sundaram, Lubing Wu, Jane Matejka, Brittany Hobbie, Nourhan Hamadi, Simone Morris, Zhengming Chen, Ivo Sah Bander, Madhu Ouseph, Jia Ruan, Amy Chadburn, Adam Kittai, Richard Furman

Blood (2025) 146 (Supplement 1): 3681.

https://doi.org/10.1182/blood-2025-3681

Published: 2025

Journal Articles

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Blood (2025) 146 (Supplement 1): 3671.

https://doi.org/10.1182/blood-2025-3671

Published: 2025

Journal Articles

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer, Robert Ryan, Ajay Major, Natalie Grover, Kelsey Baron, Talal Hilal, Adrienne Nedved, Taylor Brooks, Arjun Ravishankar, Tarsheen Sethi, Brian Hill, Yucai Wang, Allison Bock, Adam Kittai, Matthew Matasar, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2025-1956

Published: 2025

Journal Articles

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Aseel Alsouqi, Ying Huang, Lindsey Rike, Lillian Dweik, Swetha Hinton, Mollie Moran, Mark Reid, Corinne Hoffman, Cara Grantier, Margaret Lucas, Amneet Bajwa, Seema Bhat, Michael Grever, Kerry Rogers, Harsh Shah, Jennifer Woyach, Adam Kittai

Blood (2025) 146 (Supplement 1): 1953.

https://doi.org/10.1182/blood-2025-1953

Published: 2025

Journal Articles

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison

Blood (2022) 140 (20): 2142–2145.

https://doi.org/10.1182/blood.2022016953

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Allison M. Winter, MD, Loretta J. Nastoupil, MD, Melody R. Becnel, MD, James R. Cerhan, MD PhD, Thomas M. Habermann, MD, Brian K. Link, MD, Matthew J. Maurer, MS, Bita Fakhri, MD MPH, Prathima Reddy, MD, Stephen D. Smith, MD, Dhruvika Mukhija, MD, Deepa Jagadeesh, MD MPH, Amrita Desai, MD, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD, Pooja Mehra, MD, Craig A. Portell, MD, Christopher R. D'Angelo, MD, Vaishalee P. Kenkre, MD, Max L. Goldman, MD, Oscar Calzada, BS, Jonathon B. Cohen, MD MS, Mohammad Junaid Hussain, MD, Nilanjan Ghosh, MD PhD, Yang Liu, MD, Stefan Klaus Barta, MD MRCP, MS, Paolo F Caimi, MD, Adam Kittai, MD, Alexey V Danilov, MD PhD, Timothy Tiutan, MD, Peter Martin, FRCPC, MD MS, Nathalie Danielson, MSN, RN, ACNP-BC, Manali Kamdar, MD, Abhigna Kodali, MD, Andrew M. Evens, DO, MSc, Brad S Kahl, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 4146.

https://doi.org/10.1182/blood-2018-99-118530

Published: 2018

Journal Articles

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Scott R Best, BS, Adam Kittai, MD, Taylor Rowland, BS, Nur Bruss, BS, Stephen E Spurgeon, MD, Allison Berger, PhD, Amy Moran, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2018-99-115086

Published: 2018

Journal Articles

Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia

Max J. Gordon, MD, Michael C Churnetski, BS, Hamood Alqahtani, MBBS, Xavier Issac Rivera, BS, Adam Kittai, MD, Nur Bruss, BS, Sheila Hoff, BSN, Michael Y. Choi, MD, Jonathon B. Cohen, MD MS, Daniel Persky, MD, Byung Park, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2018-99-113917

Published: 2018

Journal Articles

Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells

Adam Kittai, MD, Scott R Best, BS, Taylor Rowland, BS, Nur Bruss, BS, Craig Okada, MD PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2018-99-113179

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib

Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm

Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL)

Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia

Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only